Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer

Part of paid clinical trials in St Louis, Missouri.

Sponsor
Washington University School of Medicine
Study ID
NCT05521997
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Advanced Cervical Carcinoma
  • Cancer of the Cervix
  • Cervical Cancer
  • Cervix Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Telaglenastat — DRUG
    -800 mg twice per day by mouth
  • Radiation treatment — RADIATION
    * Standard of care * External beam radiation therapy delivered daily 4 days a week and 1 day per week of brachytherapy.
  • Cisplatin — DRUG
    * Standard of care * Weekly administration of cisplain

Study Details

Advanced cervical cancer patients treated with standard of care (SOC) chemoradiation plus glutaminase inhibition with telaglenastat (CB-839) will have increased progression-free survival (PFS) compared to historical rates for patients receiving SOC chemoradiation alone.

Key Dates

Start date
Jul 31, 2026
Status verified
Mar 2026
Primary completion
Oct 7, 2032
Completion
Oct 7, 2032

Study Design

Enrollment
42 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Control Arm: Standard of Care Chemoradiation
    -Participants will receive 7 weeks of standard of care chemoradiation.
  • Experimental: Experimental Arm #1: Telaglenastat + Standard of Care Chemoradiation
    -Participants will receive 2 weeks of telaglenastat and 7 weeks of standard of care chemoradiation plus telaglenastat.

Primary Outcome Measure

Progression-free survival (PFS) - experimental arm only [ Time Frame: Through completion of follow-up (estimated to be 24 months and 9 weeks) ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Washington University School of MedicineSt LouisMissouri63110
Julie K Schwarz, M.D., Ph.D.
[email protected]
314-608-6813
Julie K Schwarz, M.D., Ph.D. (PRINCIPAL_INVESTIGATOR)
Stephanie Markovina, M.D., Ph.D. (SUB_INVESTIGATOR)
Andrea Hagemann, M.D., MSCI (SUB_INVESTIGATOR)
Dineo Khabele, M.D. (SUB_INVESTIGATOR)
Lindsay Kuroki, M.D. (SUB_INVESTIGATOR)
L. Stewart Massad, M.D. (SUB_INVESTIGATOR)
Carolyn McCourt, M.D. (SUB_INVESTIGATOR)
Maggie Mullen, M.S. (SUB_INVESTIGATOR)
David Mutch, M.D. (SUB_INVESTIGATOR)
Matthew Powell, M.D. (SUB_INVESTIGATOR)
Premal Thaker, M.D. (SUB_INVESTIGATOR)
David DeNardo, Ph.D. (SUB_INVESTIGATOR)
Gary Patti, Ph.D. (SUB_INVESTIGATOR)
Li Ding, Ph.D. (SUB_INVESTIGATOR)
Esther Lu, Ph.D. (SUB_INVESTIGATOR)

Find similar trials in St Louis, MO

By condition
Cervical cancer
By specialty
OncologyGynecologic oncologyWomen's health
By research site
Washington University School of Medicine· St Louis, MO

Related Studies